Published: 20 October 2025General
MAM01 Monoclonal Antibody Offers 100% Malaria Protection in Trials
A study from the University of Maryland School of Medicine reported that the MAM01 monoclonal antibody achieved 100% protection against malaria at its highest dose in clinical trials. The antibody neutralises the malaria parasite (Plasmodium falciparum) before it enters the bloodstream through a single-dose administration offering months-long protection.
This is a major advancement over traditional antimalarial drugs and vaccines like RTS,S/AS01 (Mosquirix), which offer only 30-40% efficacy. India accounts for approximately 2% of global malaria cases and 2% of malaria deaths. Rajasthan's Thar Desert border districts of Barmer, Jaisalmer, and Jodhpur are identified as malaria-endemic zones, where such a long-acting prevention approach could be transformative.
0
6-axis classification
CoverageInternationalSubjectScience & TechnologyExamBasic Computer Instructor · CET Graduation · CET Senior Secondary · EO/RO · LDC · Mahila Supervisor · Patwar · PTI · RAS · REET · RPSC SI · School Lecturer · Senior Computer Instructor · Senior Teacher · UPSC · Vanpal · Both
Practice MCQ from this story
SolveTap an option below. Correct or incorrect feedback appears instantly.
Linked questionMedium
The MAM01 monoclonal antibody, which achieved 100% protection in clinical trials, targets which disease?
Explanation · Correct answer CMAM01 is a human monoclonal antibody studied for protection against malaria. In an early-stage controlled human malaria infection trial, the highest tested dose produced complete protection in malaria-naive adults, showing proof of principle against Plasmodium falciparum malaria.
Frequently asked questions
What is the MAM01 monoclonal antibody and what protection does it offer against malaria?
**MAM01** is a **monoclonal antibody** that has shown **100% protection against malaria** in clinical trials, representing a potential breakthrough in malaria prevention. It targets the parasite at a specific stage to prevent infection.
What makes MAM01 different from existing malaria vaccines?
Unlike current vaccines like **RTS,S (Mosquirix)** which offer limited efficacy (~50%), **MAM01 provides 100% protection** in trials. Monoclonal antibodies offer a faster, targeted immune response, potentially offering longer-lasting protection from a single dose.
How does a monoclonal antibody like MAM01 work against malaria?
**MAM01** works by targeting a specific protein on the **Plasmodium falciparum malaria parasite** (likely circumsporozoite protein or similar), neutralising it before it can infect liver cells. This 'passive immunity' approach bypasses the need for the body's own immune response.
What is the significance of 100% malaria protection for global health?
**100% malaria protection** from MAM01 trials represents a potential game-changer in global health. Malaria kills over **600,000 people annually** (mostly children in Africa). A near-100% effective prevention tool could dramatically reduce malaria mortality.
In which stage are the MAM01 malaria antibody trials?
**MAM01** showed **100% protection** in Phase 1/2 clinical trials, demonstrating excellent safety and efficacy. Further large-scale Phase 3 trials are needed before regulatory approval and widespread deployment can occur in malaria-endemic countries.
